Silvan Tuerkcan
Stock Analyst at Citizens JMP
(4.72)
# 693
Out of 4,455 analysts
418
Total ratings
44.4%
Success rate
17.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintained: Buy | $8 → $11 | $6.34 | +73.50% | 44 | Jun 23, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $19 → $21 | $18.56 | +13.15% | 37 | May 20, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | n/a | $1.75 | - | 7 | May 8, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | $28 → $30 | $16.68 | +79.86% | 45 | Apr 28, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $86 → $80 | $54.92 | +45.67% | 56 | Jan 30, 2026 | |
| NUVB Nuvation Bio | Maintained: Buy | $8 → $10 | $5.65 | +76.99% | 6 | Nov 20, 2025 | |
| BNTC Benitec Biopharma | Maintained: Buy | $20 → $22 | $12.37 | +77.85% | 26 | Nov 4, 2025 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $9 | $4.22 | +113.27% | 4 | Oct 31, 2025 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $45 | $36.74 | +22.48% | 4 | Oct 13, 2025 | |
| JSPR Jasper Therapeutics | Maintained: Buy | $12 → $6 | $0.341 | +1,659.53% | 12 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.68 | +673.81% | 12 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $9.29 | +61.46% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.81 | - | 29 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $54.77 | -8.71% | 53 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.43 | n/a | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.58 | n/a | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $16.10 | n/a | 31 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.83 | n/a | 23 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $12.43 | n/a | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.85 | n/a | 3 | May 7, 2020 |
Taysha Gene Therapies
Jun 23, 2026
Maintained: Buy
Price Target: $8 → $11
Current: $6.34
Upside: +73.50%
Relay Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $19 → $21
Current: $18.56
Upside: +13.15%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.75
Upside: -
Intellia Therapeutics
Apr 28, 2026
Maintained: Buy
Price Target: $28 → $30
Current: $16.68
Upside: +79.86%
CRISPR Therapeutics AG
Jan 30, 2026
Maintained: Buy
Price Target: $86 → $80
Current: $54.92
Upside: +45.67%
Nuvation Bio
Nov 20, 2025
Maintained: Buy
Price Target: $8 → $10
Current: $5.65
Upside: +76.99%
Benitec Biopharma
Nov 4, 2025
Maintained: Buy
Price Target: $20 → $22
Current: $12.37
Upside: +77.85%
Foghorn Therapeutics
Oct 31, 2025
Maintained: Buy
Price Target: $9
Current: $4.22
Upside: +113.27%
IDEAYA Biosciences
Oct 13, 2025
Reiterated: Buy
Price Target: $45
Current: $36.74
Upside: +22.48%
Jasper Therapeutics
Sep 22, 2025
Maintained: Buy
Price Target: $12 → $6
Current: $0.341
Upside: +1,659.53%
Sep 17, 2025
Reiterated: Buy
Price Target: $13
Current: $1.68
Upside: +673.81%
Sep 12, 2025
Reiterated: Buy
Price Target: $15
Current: $9.29
Upside: +61.46%
Aug 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $4.81
Upside: -
Jul 29, 2025
Reiterated: Buy
Price Target: $50
Current: $54.77
Upside: -8.71%
Jun 18, 2025
Reiterated: Buy
Price Target: $6
Current: $3.43
Upside: n/a
Jun 3, 2025
Reiterated: Buy
Price Target: $4
Current: $0.58
Upside: n/a
May 9, 2025
Downgraded: Hold
Price Target: n/a
Current: $16.10
Upside: n/a
Mar 14, 2025
Maintained: Buy
Price Target: $6
Current: $2.83
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Jan 26, 2023
Maintained: Buy
Price Target: $18
Current: $12.43
Upside: n/a
May 7, 2020
Rated: Hold
Price Target: n/a
Current: $2.85
Upside: n/a